Pentamice Fact Sheet

Curia offers a comprehensive approach for the efficient generation of therapeutic antibodies. This process leverages the PentaMice® platform, a unique set of mice encompassing a diverse range of MHC haplotypes. This comprehensive approach facilitates robust T cell-mediated immune responses, maximizing the production of high-quality antibodies in vivo.

Subsequently, the humanization of client-derived IgG molecules minimizes the potential for immunogenicity in patients. This is achieved through the grafting of complementarity-determining regions (CDRs) from the novel sequences onto a human antibody framework. This technique strives to preserve the original binding affinity and specificity of the antibody. To ensure optimal functionality, back mutations are strategically introduced to enhance CDR loop stability and promote efficient VH-VL domain pairing. Finally, the humanized antibody undergoes recombinant production and kinetic evaluation before final delivery of the sequence and associated materials.

Explore how our streamlined process minimizes the time and resources required to transition promising antibody candidates from discovery to the clinical setting.